A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07291414
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Educational Intervention — OTHER
    Receive educational materials and resources
  • Electronic Health Record Review — OTHER
    Ancillary studies
  • Follow-Up — PROCEDURE
    Receive follow-up contact
  • Internet-Based Intervention — OTHER
    Use self-monitoring platform
  • Interview — OTHER
    Ancillary studies
  • Survey Administration — OTHER
    Ancillary studies

Study Details

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Key Dates

Start date
Jan 9, 2026
Status verified
Jan 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: Health services research (self-monitoring platform)
    Patients use the self-monitoring platform to track medication-related safety events and issues at home for 6 months. Patients may receive relevant educational materials and resources via the platform or by email and/or receive follow-up contact from a nurse practitioner as needed over the 6 months. Patients are encouraged to continue using the platform for an additional 6 months after the study period, as desired.

Primary Outcome Measure

Self-reported system usability [ Time Frame: Up to 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109
Yun Jiang
[email protected]
734-763-3705
Yun Jiang (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By condition
Breast cancerColorectal cancerLung cancerProstate cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncologyLung oncologyLung diseaseProstate oncologyMen's healthUrology
By research site
University of Michigan Comprehensive Cancer Center· Ann Arbor, MI

Related Studies